Table 1.
Role of the advanced glycation end products (AGEs)-receptor for advanced glycation end product (RAGE) axis in cancer progression.
| Cell Lines | Study Type/Samples | Mechanisms of Action | References |
|---|---|---|---|
| Human colon adenocarcinoma (Caco-2) | In vitro | ↑ERK1/2, ↑MAPK | [27] |
| Human colon carcinoma (Colo320 and WiDr) | In vitro | ↑NF-κB, ↑ERK | [13] |
| Human erythroleukemia (HEL) | In vitro | ↑MAPK, ↑PI3K, ↑JAK/STAT | [33] |
| Human breast cancer (MCF-7) | In vitro | ↑VEGF | [24] |
| Human breast tumor samples | In vivo | ↑NF-κB | [42] |
| Human hepatocellular carcinoma (Hep3B and HepG2) | In vitro | ↑VEGF | [21] |
| Glioma (C6) | In vitro | ↑NF-κB | [43] |
| Human colorectal carcinoma (HCT116) | In vitro | ↑ChREBP | [28] |
| Human hepatocellular carcinoma (HepG2) | In vitro | ↑ChREBP | [28] |
| Human oral cancer (SAS) | In vitro | ↑ERK, ↑MMP2, ↑MMP9 | [39] |
| Human prostate cancer (PC-3) | In vitro | ↑PI3K/Akt | [22] |
| Human breast cancer (MDA-MB-231) | In vitro | ↑ERK1/2, ↑STAT3, ↑p38, ↑MAPK, ↑MMP-9 | [25] |
| Human gastric cancer (SGC7901) and human gastric tumors samples | In vitro/ In vivo | ↑ERK/Sp1/MMP2 | [34] |
| Rat pheochromocytoma (PC12) | In vitro | ↑NF-κB | [44] |
| Human breast cancer (MCF-7) | In vitro | ↑MMP9, ↑ERK1/2 | [37] |
| Human oral cancer (SAS) | In vitro | ↓Nrf-2, ↓p53 | [23] |
| Colorectal cancer (human samples) | In vivo | ↑ERK/SP1/MMP2 | [35] |
Akt; protein kinase B, ERK; extracellular signal-regulated kinase, JAK; Janus kinase, MAPK; mitogen-activated protein kinase, MMPs; matrix metalloproteinases, NF-κB; nuclear factor kappa B, Nrf-2; Nuclear factor (erythroid-derived 2)-like 2, PI3K; phosphatidylinositide 3-kinase, STAT3; signal transducer and activator of transcription 3.The arrow pointing up (↑) means increase or upregulation.The arrow pointing down (↓) means decrease or downregulation.